This recent article, “Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma”, initially published online in September 2014 by the Clinical Cancer Research medical journal, informs about an apparent advancement made in the treatment on malignant pleural mesothelioma (MPM).
From the Abstract for this medical journal article:
Purpose: Amatuximab is a chimeric monoclonal antibody to mesothelin, a cell surface glycoprotein highly expressed in malignant pleural mesothelioma (MPM). On the basis of its synergy with chemotherapy in preclinical studies, we evaluated the antitumor activity of amatuximab plus pemetrexed and cisplatin in patients with unresectable MPM.
Conclusions: Amatuximab with pemetrexed and cisplatin was well tolerated with objective tumor response or stable disease rate of 90% by independent radiologic review. Although [progression-free survival (PFS)] was not significantly different from historical controls, the median [overall survival (OS)] was 14.8 months with a third of patients alive and 5 continuing to receive amatuximab at the time of analysis.
We will continue to monitor the medical journal for mesothelioma treatment developments.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.